Merrill Lynch (MER
is seen lower on a Moody's statement that investigations of investment banks could lead to criminal indictments and ratings cuts.
S&P downgraded Sun Microsystems (SUNW) to accumulate from buy.
Seitel (SEI) signed a non-binding letter of intent to sell up to $20M of common stock in private placement to institutional investor at discount to current market price.
Express Scripts (ESRX) announced in an SEC filing that neither the company nor its DPS unit are targets in a U.S. Attorney's Office investigation... SWS Securities upgraded to strong buy.
Synopsys (SNPS) sees $0.38 EBG, $0.02 above consensus, on $185M-$186M revenue. S&P upgraded to hold from avoid.
Wild Oats Market (OATS) posted $0.03 Q1 EPS vs. breakeven on 6.2% higher sales. RBC Capital upgraded to outperform from sector perform.
Amedisys (AMED) posted $0.25 Q1 EPS vs. a $0.07 loss from continuing operations on a 44% revenue rise. In an 8-K filed on May 3, the company says it dismissed Arthur Andersen LLP as its auditors.
Kennametal (KMT) agreed to acquire Widia Group in Europe and India from Milacron for EUR 188 million.
Michaels Stores (MIK) announces that Bryan M. DeCordova, exec. vice president and CFO, plans to leave the company in the fall after an orderly transition.
Autodesk (ADSK) sees lower than expected $0.14-$0.16 Q1 EPS (pro forma) on $227M-$229M revenue.
SoundView upgraded Motorola (MOT) to strong buy from buy.
Computer Network (CMNT) sees a $0.10-$0.15 Q1 loss from continuing operations on $45M revenue, below estimates. The company citesd soft IT spending and project delays.
Pemstar (PMTR) cut Q4 guidance to about $145M sales, and a $0.21-$0.32 cash loss. Pemstar agreed to privately place up to $50M of convertible notes. Lehman downgraded to buy. JP Morgan reportedly downgraded to market perform.
BMC Software (BMC) posted $0.12 Q4 EPS from operations on 22% lower total revenue and sees $0.07-$0.09 Q1 EPS, and $0.46-$0.52 fiscal 2003 EPS on $1.352B-$1.376B revenue.
Peregrine Systems' (PRGN) board authorized an audit committee to conduct an internal investigation into potential accounting inaccuracies. CEO Steve Gardner and CFO Matt Glass resigned. The shares were sharply lower in pre-market trading.
Church & Dwight (CHD) posted $0.42 vs. $0.33 Q3 EPS from operations on a 13% sales rise.
Misonix (MSON) posted a $0.03 Q3 loss vs. a $0.48 loss (including reserve for a litigation settlement) on flat sales, citing an unfavorable product mix, and an increase in medical R&D related to the redesign of its Neuroaspirator product.
Neopharm (NEOL) says its investigational tumor-targeting agent, IL13-PE38, was designated as fast track drug development program by FDA for treatment of malignant glioma.
Sulzer Medica's (SM) Sulzer Spine-Tech unit received FDA approval to begin marketing its BP/Lordotic Interbody Fusion Device for use in anterior lumbar fusions.